Fig. 1

Demographic and clinical characteristics and sample overview for each patient. (A) Adjuvant vs. palliative treatment, chemotherapy regimen, distant metastasis (M0, liver, peritoneum or multiple sites), sex, age category and performance status according to the Eastern Cooperative Oncology Group (ECOG) scale, per patient. Red bars indicate the total number of analyzed plasma samples per patient followed by KRAS mutation status; mutated vs. wild-type or not detected, type of mutation, overall ctDNA status regardless of time point, germline mutation (if detected), yellow bars indicate the total number of analyzed tissue samples per patient followed by type of diagnostic specimen: surgical resection, biopsy, cytology, or biopsy not sufficient (NS) for analysis. (B) Overview of timepoints for ctDNA samples, CT scans and surgery for adjuvant (blue lines) and palliative (red lines) treated patients. Green depicts negative for ctDNA, no evidence of disease (NED) or radiologic regression, red depicts positive for ctDNA, recurrence or radiologic progression. Cross marks timepoint for death and circle means that the patient was alive at last follow-up.